An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered Daily in Patients With Refractory Solid Tumors or Lymphoma
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs CUDC 427 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 28 Nov 2012 Encouraging results have been observed in this trial according to a Curis media release. Results are expected to be presented at a conference in mid-2013.
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Mar 2012 Planned end date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History